These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 31626562)

  • 1. Targeting Proteases in Cystic Fibrosis Lung Disease. Paradigms, Progress, and Potential.
    McKelvey MC; Weldon S; McAuley DF; Mall MA; Taggart CC
    Am J Respir Crit Care Med; 2020 Jan; 201(2):141-147. PubMed ID: 31626562
    [No Abstract]   [Full Text] [Related]  

  • 2. Cystic Fibrosis: Translating Molecular Mechanisms into Effective Therapies.
    Jennings MT; Flume PA
    Ann Am Thorac Soc; 2018 Aug; 15(8):897-902. PubMed ID: 29812963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The protease-antiprotease battle in the cystic fibrosis lung.
    Balfour-Lynn IM
    J R Soc Med; 1999; 92 Suppl 37(Suppl 37):23-30. PubMed ID: 10472249
    [No Abstract]   [Full Text] [Related]  

  • 4. Influence of DNA on the activities and inhibition of neutrophil serine proteases in cystic fibrosis sputum.
    Dubois AV; Gauthier A; Bréa D; Varaigne F; Diot P; Gauthier F; Attucci S
    Am J Respir Cell Mol Biol; 2012 Jul; 47(1):80-6. PubMed ID: 22343221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reshma Kewalramani.
    Mullard A
    Nat Rev Drug Discov; 2019 Nov; 18(12):896-897. PubMed ID: 31780855
    [No Abstract]   [Full Text] [Related]  

  • 6. α-Amino-α'-halomethylketones: synthetic methodologies and pharmaceutical applications as serine and cysteine protease inhibitors.
    Pace V; Castoldi L; Pregnolato M
    Mini Rev Med Chem; 2013 Jun; 13(7):988-96. PubMed ID: 22931530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protease-Antiprotease Imbalance in Bronchiectasis.
    Oriano M; Amati F; Gramegna A; De Soyza A; Mantero M; Sibila O; Chotirmall SH; Voza A; Marchisio P; Blasi F; Aliberti S
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34206113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections.
    Hisert KB; Heltshe SL; Pope C; Jorth P; Wu X; Edwards RM; Radey M; Accurso FJ; Wolter DJ; Cooke G; Adam RJ; Carter S; Grogan B; Launspach JL; Donnelly SC; Gallagher CG; Bruce JE; Stoltz DA; Welsh MJ; Hoffman LR; McKone EF; Singh PK
    Am J Respir Crit Care Med; 2017 Jun; 195(12):1617-1628. PubMed ID: 28222269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corrector combination therapies for F508del-CFTR.
    Hanrahan JW; Matthes E; Carlile G; Thomas DY
    Curr Opin Pharmacol; 2017 Jun; 34():105-111. PubMed ID: 29080476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secretory leukocyte protease inhibitor in cystic fibrosis.
    Stromatt SC
    Agents Actions Suppl; 1993; 42():103-10. PubMed ID: 8102834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elastolytic proteases: inflammation resolution and dysregulation in chronic infective lung disease.
    Taggart CC; Greene CM; Carroll TP; O'Neill SJ; McElvaney NG
    Am J Respir Crit Care Med; 2005 May; 171(10):1070-6. PubMed ID: 15695494
    [No Abstract]   [Full Text] [Related]  

  • 12. EPI-hNE4, a proteolysis-resistant inhibitor of human neutrophil elastase and potential anti-inflammatory drug for treating cystic fibrosis.
    Attucci S; Gauthier A; Korkmaz B; Delépine P; Martino MF; Saudubray F; Diot P; Gauthier F
    J Pharmacol Exp Ther; 2006 Aug; 318(2):803-9. PubMed ID: 16627747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteases and antiproteases in cystic fibrosis: pathogenetic considerations and therapeutic strategies.
    Birrer P
    Respiration; 1995; 62 Suppl 1():25-8. PubMed ID: 7792437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Designing trials for new cystic fibrosis modulators.
    Cunningham S; McColley SA
    Lancet Respir Med; 2018 Jul; 6(7):484-486. PubMed ID: 29859920
    [No Abstract]   [Full Text] [Related]  

  • 15. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
    Ong T; Ramsey BW
    Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Looking at the proteases from a simple perspective.
    Castro HC; Abreu PA; Geraldo RB; Martins RC; dos Santos R; Loureiro NI; Cabral LM; Rodrigues CR
    J Mol Recognit; 2011; 24(2):165-81. PubMed ID: 21360607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New drug treatments for cystic fibrosis.
    Smyth RL
    BMJ; 2020 Jan; 368():m118. PubMed ID: 31959620
    [No Abstract]   [Full Text] [Related]  

  • 18. Potentiators for cystic fibrosis - targeting the underlying molecular defect.
    Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
    Paediatr Respir Rev; 2015 Jun; 16(3):162-4. PubMed ID: 26002404
    [No Abstract]   [Full Text] [Related]  

  • 19. Inactivation of IL-6 and soluble IL-6 receptor by neutrophil derived serine proteases in cystic fibrosis.
    McGreal EP; Davies PL; Powell W; Rose-John S; Spiller OB; Doull I; Jones SA; Kotecha S
    Biochim Biophys Acta; 2010; 1802(7-8):649-58. PubMed ID: 20438838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study of intracellular localization of the proteolytic enzyme complex and its protein inhibitors in bombyx grain].
    Iarygin DV; Min'kova NO; Filippovich IuB
    Ontogenez; 2012; 43(5):325-32. PubMed ID: 23101406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.